Navigation Links
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Date:12/18/2007

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers. Developed as a tumor-targeted anticancer agent, that actively seeks out and destroys metastatic cancers, Rexin-G exhibits unprecedented single-agent efficacy where other agents, including targeted biologics, have failed. Moreover, Rexin-G has established an exemplary record of clinical safety, virtually eliminating the systemic toxicities routinely encountered with chemotherapies, thus enhancing quality of life.

*(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

This recent regulatory approval and licensure of Rexin-G in the Philippines is noteworthy in that Rexin-G(R) is among the first gene-based medicines to be approved anywhere in the world, and remarkable in that it is the first targeted gene delivery system ever developed that actually works in humans. However, such individual accomplishments are rarely heralded by the intrepid physicians and scientists at Epeius Biotechnologies, whose mission runs contrary to so many blue-sky biotechnology companies that are quick to "sell (i.e., promote) the story," only to disappoint the patients, who remain the most vulnerable of society.

According to Dr. Frederick L. Hall, President and CEO of Epeius, "It is most fitting that Rexin-G receives its first product registration in the Philippines which brought forth the stellar physician-scientist whose drive and determination to engineer a better medicine made Rexin-G possible, and also it was first in the Philippines where the dedicated clinicians, oncologists, regulatory authorities, and medical institutions worked tirelessly for years to bring this targeted genetic medicine to the
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ( ... Regulatory Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... will provide a detailed overview of the key areas of ... Hong Kong , Macau ... - All important aspects of gaining and maintaining ...
(Date:9/2/2015)... -- Seeger Weiss LLP is reporting that Zimmer Holdings Inc.,s ... 2015. Since the product was approved ... NexGen knee implant surpassed FDA investigation and mandatory product ... that the product is substantially similar to a preexisting ... In 2001, Zimmer began distributing High ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced the ... UK - November 16-17, 2015)" conference to their ... concerning Pharmacovigilance are a major departure in terms of ... . The intention of the course is to ... they overlap and fit together and what Companies need ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... ... September 03, 2015 , ... ... providers, has been retained to lead a national chief executive officer ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:9/3/2015)... ... September 03, 2015 , ... Dr. Robert Winchell has been appointed director ... Acute Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 27. He will serve on ... expert in care for the critically injured and the development, design and operations of ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology ... test that may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed ... are often caused by HPV infections, which have a high rate of success in ...
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the ... will be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ... and 17 at the Olympia London, booth #F33 , Be the first to get ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Act (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more ... employers (1,000+ employees), according to data released from the 2014 United Benefit Advisors ...
Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... The experts reveal that lot more funds are needed from ... deaths of children under five by two-thirds.// ,Five ... experts, whose paper is one of the series of papers ... high-level meeting hosted by the journal, UNICEF and the Norwegian ...
... drug extensively used to treat acne can cause depression. ... animals.// ,Recently, the drug- Roaccutane, which effectively ... severe side-effects like suicidal behaviour. Though the packaging of ... occurrence of such side-effects is not known.,It has not ...
... an anti-cancer drug called Biomab-EGFR and had Shah Rukh Khan ... told reporters that the drug would be priced at 40 ... "Today we join the exclusive league of MAb developers worldwide. ... she added. She also told the drug was undergoing regulatory ...
... and Kashmir has a new problem to contend with now ... there are 745 such cases in the insurgency-hit state, unofficial ... there were only two cases reported, writes Grassroots Features. The ... the infection rate among the high-risk groups (STD-infected) at 0.95 ...
... arm in a motorcycle accident. She has become the first woman to ... own nerves. ,She talked about how she used it ... able to eat in a conventional way since her accident of over ... me.” ,Very often patients fitted with high-tech prosthetic limbs ...
... A new web site at the University of California, ... will enable people from around the world// to self-report ... other cholesterol drugs. ,“This line of research ... heart disease and cholesterol are familiar with the benefits ...
Cached Medicine News:Health News:Child death reduction needs five times more funds 2Health News:Acne drug may cause depression 2Health News:Kashmir Grapples with Growing AIDS 2Health News:Kashmir Grapples with Growing AIDS 3Health News:Bionic Women –No longer the Stuff of Science Fictio 2Health News:Patients Can Report Statins' Adverse Effects on New Web Site 2
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... as either EDTA K2 or EDTA ... ions and therefore blocks the coagulation ... an EDTA anticoagulated blood sample are ... EDTA tubes are for the examination ...
Medicine Products: